Heterogeneity of Acetylcholine Receptor Autoantibody-Mediated Complement Activity in Patients With Myasthenia Gravis.

ABSTRACT:

Background and objectives

Autoantibodies targeting the acetylcholine receptor (AChR), found in patients with myasthenia gravis (MG), mediate pathology through 3 mechanisms: complement-directed tissue damage, blocking of the acetylcholine binding site, and internalization of the AChR. Clinical assays, used to diagnose and monitor patients, measure only autoantibody binding. Consequently, they are limited in providing association with disease burden, understanding of mechanistic heterogeneity, and monitoring therapeutic response. The objective of this study was to develop a cell-based assay that measures AChR autoantibody-mediated complement membrane attack complex (MAC) formation.

Methods

An HEK293T cell line-modified using CRISPR/Cas9 genome editing to disrupt expression of

SUBMITTER: Obaid AH 

PROVIDER: S-EPMC9128035 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature